Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 959-969

  Duong, Hong Quan ^a,b,e   Yi, Yong Weon ^a,b   Kang, Hyo Jin ^a   Hong, Young Bin ^a,f   Tang, Wenxi ^c   Wang, Antai ^c,d,g   Seong, Yeon Sun ^b   Bae, Insoo ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

^c Department of Biostatistics ^*  (South Korea)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e DUY TAN UNIVERSITY   (Viet Nam)

^f Ewha Womans University School of Medicine   (South Korea)

^g NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Gemcitabine; MRP5; NRF2; PIK 75; Synergism

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 5; PIK 75; PROTEASOME; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPORTER GENE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; HYDRAZONES; MICE; NF-E2-RELATED FACTOR 2; PANCREATIC NEOPLASMS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896716558     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2229     Document Type: Article

References (50)

1. American Cancer Society: Cancer Facts and Figures 2013. American Cancer Society, Atlanta, GA, 2013.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
3. Cowgill SM and Muscarella P: The genetics of pancreatic cancer. Am J Surg 186: 279-286, 2003.
4. Li D and Jiao L: Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 33: 3-14, 2003.
5. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefic with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
6. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518, 2009.
7. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
8. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E and Kakolyris S: Molecular pathogenesis of pancreatic cancer and clinical perspective. Oncology 81: 259-272, 2011.
9. Bryan HK, Olayanju A, Goldring CE and Park BK: The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85: 705-717, 2013.
10. Mitsuishi Y, Motohashi, H and Yamamoto M: The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2: 200, 2012.
11. Ma Q: Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53: 401-426, 2013.
12. Niture SK, Khatri R and Jaiswal AK: Regulation of NRF2-an update. Free Radic Biol Med. doi: 10.1016/k.freeradbiomed.2013.02.008, 2013.
13. Kang HJ, Hong YB, Kim HJ and Bae I: CR6-interacting factor 1 (CRIF1) regulates NF-E2-related factor 2 (NRF2) protein stability by proteasome-mediated degradation. J Biol Chem 285: 21258-21268, 2010.
14. Martín-Montalvo A, Villalba JM, Navas P and de Cabo R: NRF2, cancer and calorie restriction. Oncogene 30: 505-520, 2011.
15. Hayes JD and McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
16. DeNicola GM, Karreth FA, Humpton TJ, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
17. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2 related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
18. Yamadori T, Ishii Y, Homma S, et al: Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 31: 4568-4577, 2012.
19. Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
20. Hong YB, Kang HJ, Kwon SY, et al: Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 39: 463-472, 2010.
21. Lister A, Nedjadi T, Kitteringham NR, et al: Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10: 37, 2011.
22. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs and enzyme inhibitors. Adv Enz Regul 22: 27-55, 1984.
23. Kang HJ, Kim HJ, Kim SK, et al: BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem 281: 14654-14662, 2006.
24. Kang HJ, Kim HJ, Rih JK, et al: BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem 281: 13047-13056, 2006.
25. Duong HQ, Kim HJ, Kang HJ, Seong YS and Bae I: ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncol Rep 27: 182-188, 2012.
26. Knight ZA, Gonzalez B, Feldman ME, et al: A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125: 733-747, 2006.
27. Loboda A, Was H, Jozkowicz A and Dulak J: Janus face of Nrf2-HO-1 axis in cancer - friend in chemoprevention, foe in anticancer therapy. Lung Cancer 60: 1-3, 2008.
28. Kensler TW and Wakabayashi N: Nrf2: friend or foe for chemoprevention? Carcinogenesis 31: 90-99, 2010.
29. Müller T and Hengstermann A: Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. Chem Res Toxicol 25: 1805-1824, 2012.
30. Sporn MB and Liby KT: NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12: 564-571, 2012.
31. Hayes JD, McMahon M, Chowdhry S and Dinkova-Kostova AT: Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 13: 1713-1748, 2010.
32. Shelton P and Jaiswal AK: The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J 27: 414-423, 2013.
33. Hur W and Gray NS: Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol 15: 162-173, 2011.
34. Yotsumoto F, Fukami T, Yagi H, et al: Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci 101: 2351-2360, 2010.
35. Cartee L and Kucera GL: Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 41: 403-412, 1998.
36. Huynh H, Soo KC, Chow PK and Tran E: Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 6: 138-146, 2007.
37. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
38. Srivastava AK and Pandey SK: Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem 182: 135-141, 1998.
39. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A and Hayes JD: Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32: 3765-3781, 2013.
40. Jain AK and Jaiswal AK: GSK-3β acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem 282: 16502-16510, 2007.
41. Niture SK, Jain AK, Shelton PM and Jaiswal AK: Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. J Biol Chem 286: 28821-28832, 2011.
42. Niture SK, Jain AK and Jaiswal AK: Antioxidant-induced modification of INrf2 cysteine 151 and PKC-δ-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci 122: 4452-4464, 2009.
43. Donadelli M, Costanzo C, Beghelli S, et al: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106, 2007.
44. Duong HQ, Hong YB, Kim JS, et al: Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. J Cell Mol Med 17: 1261-1270, 2013.
45. Haimeur A, Conseil G, Deeley RG and Cole SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53, 2004.
46. Dallas S, Schlichter L and Bendayan R: Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflus of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J Pharmacol Exp Ther 309: 1221-1229, 2004.
47. Hagmann W, Jesnowski R and Löhr JM: Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 12: 740-747, 2010.
48. Oguri T, Achiwa H, Sato S, et al: The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 5: 1800-1806, 2006.
49. Satoh H, Moriguchi T, Takai J, Ebina M and Yamamoto M: Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 73: 4158-4168, 2013.
50. Arlt A, Sebens S, Krebs S, et al: Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32: 4825-4835, 2013.